The genetic determinants of the CYP3A5 polymorphism E Hustert, M Haberl, O Burk, R Wolbold, YQ He, K Klein, AC Nuessler, ... Pharmacogenetics and Genomics 11 (9), 773-779, 2001 | 835 | 2001 |
NAD (P) H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity L Wojnowski, B Kulle, M Schirmer, G Schlüter, A Schmidt, ... Circulation 112 (24), 3754-3762, 2005 | 577 | 2005 |
Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome H Hahn, L Wojnowski, AM Zimmer, J Hall, G Miller, A Zimmer Nature medicine 4 (5), 619-622, 1998 | 508 | 1998 |
Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA I Koch, R Weil, R Wolbold, J Brockmöller, E Hustert, O Burk, A Nuessler, ... Drug Metabolism and Disposition 30 (10), 1108-1114, 2002 | 416 | 2002 |
Endothelial apoptosis in Braf-deficient mice L Wojnowski, AM Zimmer, TW Beck, H Hahn, R Bernal, UR Rapp, ... Nature genetics 16 (3), 293-297, 1997 | 398 | 1997 |
Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit … G Spanier, H Xu, N Xia, S Tobias, S Deng, L Wojnowski, U Forstermann, ... J Physiol Pharmacol 60 (Suppl 4), 111-116, 2009 | 352 | 2009 |
Identification and functional characterization of eight CYP3A4 protein variants R Eiselt, TL Domanski, A Zibat, R Mueller, E Presecan-Siedel, E Hustert, ... Pharmacogenetics and Genomics 11 (5), 447-458, 2001 | 340 | 2001 |
Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene K Gellner, R Eiselt, E Hustert, H Arnold, I Koch, M Haberl, CJ Deglmann, ... Pharmacogenetics and Genomics 11 (2), 111-121, 2001 | 335 | 2001 |
Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4 E Hustert, A Zibat, E Presecan-Siedel, R Eiselt, R Mueller, C Fuß, I Brehm, ... Drug Metabolism and Disposition 29 (11), 1454-1459, 2001 | 297 | 2001 |
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus LK Kamdem, F Streit, UM Zanger, J Brockmoller, M Oellerich, ... Clinical chemistry 51 (8), 1374-1381, 2005 | 279 | 2005 |
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats S Steven, M Oelze, A Hanf, S Kröller-Schön, F Kashani, S Roohani, ... Redox biology 13, 370-385, 2017 | 261 | 2017 |
Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma H Hahn, L Wojnowski, K Specht, R Kappler, J Calzada-Wack, D Potter, ... Journal of Biological Chemistry 275 (37), 28341-28344, 2000 | 253 | 2000 |
Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine O Burk, H Tegude, I Koch, E Hustert, R Wolbold, H Glaeser, K Klein, ... Journal of Biological Chemistry 277 (27), 24280-24288, 2002 | 247 | 2002 |
The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated … O Burk, I Koch, J Raucy, E Hustert, M Eichelbaum, J Brockmöller, ... Journal of Biological Chemistry 279 (37), 38379-38385, 2004 | 240 | 2004 |
Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver N Kassner, K Huse, HJ Martin, U Gödtel-Armbrust, A Metzger, I Meineke, ... Drug Metabolism and Disposition 36 (10), 2113-2120, 2008 | 224 | 2008 |
GSEA-SNP: applying gene set enrichment analysis to SNP data from genome-wide association studies M Holden, S Deng, L Wojnowski, B Kulle Bioinformatics 24 (23), 2784-2785, 2008 | 213 | 2008 |
Cytochrome P450 3A and their regulation O Burk, L Wojnowski Naunyn-Schmiedeberg's archives of pharmacology 369, 105-124, 2004 | 200 | 2004 |
Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms S Deng, T Yan, C Jendrny, A Nemecek, M Vincetic, U Gödtel-Armbrust, ... BMC cancer 14, 1-11, 2014 | 182 | 2014 |
Genetics of the variable expression of CYP3A in humans L Wojnowski Therapeutic drug monitoring 26 (2), 192-199, 2004 | 179 | 2004 |
Craf-1 protein kinase is essential for mouse development L Wojnowski, LF Stancato, AM Zimmer, H Hahn, TW Beck, AC Larner, ... Mechanisms of development 76 (1-2), 141-149, 1998 | 172 | 1998 |